Nikolaus Gasche – Biome Diagnostics | BiomeDx

BiomeDx Wins Startup Audience Award

Nikolaus Gasche — Tue, 08 Nov 2022 15:20:52 +0000

Vienna, November 7, 2022 – Biome Diagnostics reaches second place in the Startup competition at the Web Summit in Lisbon and wins the public vote with 56 percent of the votes. The Web Summit is one of the most important and largest tech conferences in Europe. Around 2,000 young companies presented their technologies and business models in front of international investors. The approach and vision…

Source

Digitization of Life Sciences

Nikolaus Gasche — Sun, 30 Oct 2022 16:44:00 +0000

The 17th year of International Conference on Genomics by BGI – China’s leading genomics company CHENGDU, October 30th: Nikolaus Gasche from Biome Diagnostics has participated in the session on “Digitization of Life Sciences” at the ICG-17 conference on 30th October 2022 which took place in Chengdu. The session was included other relevant leaders from around the world presenting on topics such…

Source

The Advamed MedTech Conference 2022

Nikolaus Gasche — Wed, 26 Oct 2022 16:30:13 +0000

The MedTech Conference is a must attend event for the industry’s prominent and most promising companies. BOSTON, October 24-26th: Biome Diagnostics has participated in the three-day conference on between 24-26th October 2022 in Boston, organised by Advamed, the global homecoming for any medtech company. Several leaders from the industry, investors and politicians took the stage to share their…

Source

Poster: 55th Austrian Society for Gastroenterology and Hepatology (ÖGGH) 2022

Nikolaus Gasche — Fri, 09 Sep 2022 11:17:54 +0000

BiomeDx presents newest findings on microbiome signatures predicting colorectal cancer and adenoma. VIENNA, September 8th: At the 55th Austrian Society for Gastroenterology and Hepatology (https://aerztezeitung.at/event/55-jahrestagung-32-fortbildungskurs-der-oeggh/), the BiomeDx team presented their newest results from a machine learning analysis of colorectal cancer and adenoma microbiome…

Source

ÖGGH 2022: Analysis of colorectal cancer and adenoma microbiome signatures and the application of machine learning classification as a potential screening tool

Nikolaus Gasche — Fri, 09 Sep 2022 11:08:17 +0000

Distance-based Techniques for Personal Microbiome Identification

Nikolaus Gasche — Wed, 07 Sep 2022 19:07:17 +0000

Utility and Privacy Assessment of Synthetic Microbiome Data

Nikolaus Gasche — Wed, 07 Sep 2022 19:06:30 +0000

WCLC 2022: Introducing “BiomeOne”, a microbiome-based biomarker to predict immune checkpoint inhibitor response in NSCLC patients

Nikolaus Gasche — Tue, 16 Aug 2022 11:58:34 +0000

Intestinal microbiome as cancer hope: new predictive test makes life easier for patients

Nikolaus Gasche — Mon, 18 Jul 2022 15:40:00 +0000

VIENNA, July 2022: Vienna-based Biome Diagnostics launches the first and only gut microbiome-based predictive test to date, BiomeOne®. The test analyzes and evaluates the response to immunotherapy (ICI) against cancer and the likelihood of side effects. Clinical studies have confirmed its efficacy. BiomeOne® is certified and approved as a medical device (CE-IVD).

Source

Is data protection a hurdle or a competitive advantage?

Nikolaus Gasche — Thu, 10 Feb 2022 09:11:40 +0000

Data security is crucial to us! We use the highest standards to do so! Data is also the only possibility to develop new diagnostic methods. Hence a slippery slope! On the occasion of the European Data Protection Day (28th of January) the magazine Security-Insider interviewed our co-founder Nikolaus Gasche on that topic. Read the full article: https://www.security-insider.de/

Source